Download PDF Flyer
Impact Factor Current: 2.895
5 - Year: 3.037

Endocrine, Metabolic & Immune Disorders - Drug Targets

(Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders)

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Volume 22, Issue 14, 2022

This journal supports open access

Back Journal Home
Impact Factor
Web of Science Impact Factor

Current: 2.895
5 - Year: 3.037

Ranking & Category

  • 110th of 143 in Endocrinology & Metabolism
  • 126th of 155 in Immunology
  • 172nd of 261 in Pharmacology & Pharmacy

Topic(s) Covered

2 Topic(s)

View
Covered Disease(s)

1 Disease(s)

View

Aims & Scope

This journal is devoted to full-length/ mini-reviews and original articles based on experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to the effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbiome composition are welcome. The journal’s scope also covers neuroendocrinology, reproductive endocrinology, hormone secretion, and their effects on different organs.

Abstracted/Indexed in


BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE/Excerpta Medica, ERA 2018, Genamics, JournalSeek, Google Scholar, InCites, J-Gate, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed/Index Medicus, Open Abstracts (I4OA), Norwegian Register, PubsHub, QOAM Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.

COPE COMPLIANT
Special Offers
Endorsement(s)

"EMID-DT is a prestigious journal with a multidisciplinary coverage. Its aim is to provide cutting- edge information to readers working in different field of research ranging from immune endocrine to metabolic disorders."

Chris Galanos
Max Planck Institude, Germany

Authors' Comments

Thank you for your email. Our experience of publishing with Endocrine, Metabolic and Immune Disorders - Drug Targets has been pleasant and smooth. The reports from peer reviewers arrived within a reasonable time frame and their comments were most constructive and helpful. The editors are meticulous and responsive. We hope to publish with your esteemed journal again in the near future.


Kok Yong Chin 
(Department of Pharmacology/Bone Metabolism Research Group, Universiti Kebangsaan Malaysia Medical Centre.)

Has contributed: A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
© 2022 Bentham Science Publishers | Privacy Policy